Immix Biopharma announced dosing of an additional patient in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. Safety data enabled continued dosing of previously enrolled patients. In January 2023, the seventeenth patient was dosed with IMX-110 to-date. IMX-110 clinical trial data is expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMMX:
- Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
- Immix Biopharma’s Nexcella announces additional clinical data on NXC-201
- Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
- Nexcella to present updated NXC-201 clinical data
- Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
